AHL
IOVA icon

Abel Hall LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Abel Hall LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
25,119
+713
+3% +$2.71K 0.02% 830
2026
Q1 		$85.7K Buy
+24,406
New +$78.1K 0.02% 704

Other funds holding IOVA

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
SMAM
Sugar Maple Asset Management Sister Bay, Wisconsin $155M AUM 17.72% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Abel Hall LLC's IOVA Position: Q2 2026 in Review

Abel Hall LLC increased its Iovance Biotherapeutics (IOVA) stake by 2.9% in Q2 2026, buying an estimated $2.71K and bringing the position to 25,119 shares worth $104K. The position accounts for 0.02% of the portfolio, ranked #830.

Abel Hall LLC first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Abel Hall LLC held 25,119 shares of Iovance Biotherapeutics worth $104K as of Q2 2026.
  • Abel Hall LLC bought 713 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.71K.
  • Iovance Biotherapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #830 holding.
  • Abel Hall LLC first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.